Biological simulation is an indispensable part of biological processes. It is a computer-based mathematical solution for biological case studies. Biological simulations are model-based predictions used to understand the behavior and dynamics of biological systems. This method is increasingly used in the production of pharmaceutical drugs to find out whether the drug will fail in clinical trials, which may be due to adverse side effects or even toxicity. Therefore, this simulation is used to identify drug-related issues before entering the development phase. Biological simulation is mainly used to understand the various causes that may cause damage or damage to human organs. This specific factor is used when synthetic drugs are used to treat diseases.
The growth of the pharmaceutical industry and the increasing R&D in this field have been one of the main driving forces of this market. The expanding market of biologics and biosimilars has further promoted the market growth in the field of bio-simulation. Moreover, due to the use of the software, the software provides a mathematically compiled solution for the drug that is still under development, thereby reducing the cost of the drug production process. In addition, the increasing popularity of these drug simulation software and the use of technologically advanced QSP systems have had a positive impact on the market.
Since bio-simulation is an intermediate product used by multiple departments, this report considers the value chain analysis of the market and end-user applications. The report is titled "Global Biosimulation-Market and Technology Forecast to 2028" and has been subdivided into end users, applications and regions. End user segmentation is further subdivided into drug development, drug discovery and others according to application segmentation: end users by region are further subdivided into pharmaceutical and biotechnology companies, regulatory agencies, research institutions, contract research organizations, etc.; application details The points are also divided into software and services by product.
By 2020, the global revenue of the bio-simulation market is 4 billion US dollars, and it is expected to grow to 9 billion US dollars by 2028. During the forecast period of 2020-2028, the compound annual growth rate of this market is expected to be 11%. Based on the product, the software segment has the highest growth rate in this market. In terms of vertical integration, due to the wide application of bio-simulation technology in pharmaceutical production, the pharmaceutical and biotechnology fields have the highest market share. The increase in R&D funding provided to the pharmaceutical and biotechnology fields has been one of the key factors in the growth of this field. Due to the continuous development of research and development infrastructure and the development of a large number of drugs, North America has the highest market share in the world.
Due to North America's booming R&D departments in the fields of drug development, pharmaceuticals and biotechnology, it is expected to become the largest market. The increasing use of this technology by major players in this field has helped its market gain considerable momentum. In addition, due to regulatory practices, the use of in-computer models for patient safety and higher treatment standards has had a positive impact on the growth of the market. Due to the growth of healthcare and IT infrastructure, the Asia-Pacific region is considered to be the fastest growing segment.
Scope:
The study period of this report, ”Global Biosimulation - Market and Technology Forecast to 2028”, is from 2018-2028 and the forecast period ranges from 2020-2028. The report is segmented as End-User, Application and Region.
Reasons to buy this report: